Establishment of epidemiological cut-off values for eravacycline, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Staphylococcus aureus
Authors:
Open Access
- 16 July 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (9) , 2246-2250
Abstract
To establish the epidemiology cut-off (ECOFF) values of eravacycline against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Staphylococcus aureus, from a multi-centre study in China. We collected 2500 clinical isolates from five hospitals in China from 2017 to 2020. The MICs of eravacycline were determined using broth microdilution. The ECOFF values of eravacycline against the five species commonly causing cIAIs were calculated using visual estimation and ECOFFinder following the EUCAST guideline. The MICs of eravacycline against all the strains were in the range of 0.004–16 mg/L. The ECOFF values of eravacycline were 0.5 mg/L for E. coli, 2 mg/L for K. pneumonia and E. cloacae, and 0.25 mg/L for A. baumannii and S. aureus, consistent with the newest EUCAST publication of eravacycline ECOFF values for the populations. No discrepancy was found between the visually estimated and 99.00% ECOFF values calculated using ECOFFinder. The determined ECOFF values of eravacycline against the five species can assist in distinguishing wild-type from non-wild-type strains. Given its promising activity, eravacycline may represent a member of the tetracycline class in treating cIAIs caused by commonly encountered Gram-negative and Gram-positive pathogens.Keywords
Funding Information
- National High Level Hospital (2022-PUMCH-B-074)
This publication has 13 references indexed in Scilit:
- In vitroactivity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancerJAC-Antimicrobial Resistance, 2023
- In vitro susceptibility of common Enterobacterales to eravacycline in TaiwanJournal of Microbiology, Immunology and Infection, 2022
- In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017Antimicrobial Agents and Chemotherapy, 2020
- In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017Antimicrobial Agents and Chemotherapy, 2020
- In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2016
- Bacteriology of Spontaneous Intra-Abdominal Abscess in Patients with Crohn Disease in China: Risk of Extended-Spectrum Beta-Lactamase-Producing BacteriaSurgical Infections, 2015
- Epidemiology and Microbiology of Secondary Peritonitis Caused by Viscus Perforation: A Single-Center Retrospective StudySurgical Infections, 2015
- Tigecycline Susceptibility and the Role of Efflux Pumps in Tigecycline Resistance in KPC-Producing Klebsiella pneumoniaePLOS ONE, 2015
- Changing bacteriology of abdominal and surgical sepsisCurrent Opinion in Infectious Diseases, 2012
- Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitisCritical Care, 2010